       Document 0236
 DOCN  M9640236
 TI    Liposome-encapsulated
       (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting
       therapy of viral retinitis.
 DT    9604
 AU    Kuppermann BD; Assil KK; Vuong C; Besen G; Wiley CA; De Clercq E;
       Bergeron-Lynn G; Connor JD; Pursley M; Munguia D; Freeman WR; Department
       of Ophthalmology, University of California, San Diego,; La Jolla 92093,
       USA.
 SO    J Infect Dis. 1996 Jan;173(1):18-23. Unique Identifier : AIDSLINE
       MED/96132458
 AB    The effect of liposome-encapsulated
       (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC; cidofovir)
       was evaluated as prophylaxis in a rabbit model of experimentally induced
       retinitis caused by preretinal inoculation of herpes simplex virus type
       1 (HSV-1). Cidofovir (100 micrograms) in liposomes (0.1 mL) was injected
       intravitreally 10-120 days before retinal inoculation with HSV-1.
       Twenty-two of 26 eyes pretreated with liposome-encapsulated cidofovir
       10-60 days before HSV-1 inoculation were protected from experimentally
       induced retinitis, and 2 of 5 eyes pretreated 120 days before
       inoculation were protected. Intravitreal levels of cidofovir were low
       (0.7 microgram/mL) but detectable 120 days after injection. One
       100-micrograms intravitreal injection of liposome-encapsulated cidofovir
       appears to have a remarkably potent and prolonged (up to 4 months)
       antiviral effect in this experimental model of HSV-1 retinitis. Since
       HPMPC is even more potent against cytomegalovirus than HSV-1,
       liposome-encapsulated cidofovir may prove to be effective local therapy
       for AIDS patients with cytomegalovirus retinitis.
 DE    Animal  Antiviral Agents/*ADMINISTRATION & DOSAGE  Cytosine/*ANALOGS &
       DERIVATIVES/ADMINISTRATION & DOSAGE  Disease Models, Animal  Drug
       Carriers  Eye Infections, Viral/*DRUG THERAPY/PATHOLOGY/VIROLOGY  Herpes
       Simplex/*DRUG THERAPY/PATHOLOGY/VIROLOGY  Herpesvirus 1, Human/DRUG
       EFFECTS/PHYSIOLOGY  Injections  Liposomes  Organophosphorus
       Compounds/*ADMINISTRATION & DOSAGE  Rabbits  Retina/PATHOLOGY/VIROLOGY
       Retinitis/*DRUG THERAPY/PATHOLOGY/VIROLOGY  Support, Non-U.S. Gov't
       Support, U.S. Gov't, P.H.S.  Vitreous Body  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

